drugset / Trial / NCT04836520

SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.

NCT04836520

NaSingle-groupOpen-labelTreatment

Summary

The study is being conducted to assess effect of SHR6390 combined with anastrozole on proliferation of HR-positive HER2-negative breast cancer tumor cells before surgery.

Timeline

Start
2021-08-02
Primary completion
2023-02-28
Completion
2023-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalpiciclib Small molecule
Subject anatrozole Unknown

Indications